Mulmit

Travere Therapeutics, Inc.Travere Therapeutics, Inc.

TVTX Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2025-12-31490,728,000-62,824,000-25,546,000-0.29
2024-12-31233,175,000-323,827,000-321,545,000-4.08
2023-12-31145,238,000-388,138,000-111,399,000-1.5
2022-12-31109,460,000-319,813,000-278,482,000-4.37
2021-12-31131,836,000-199,425,000-180,091,000-3.01

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-09-02Cline Christopher R.CHIEF FINANCIAL OFFICER642
2026-08-18LYONS GARY A5,000
2026-08-18LYONS GARY A4,100
2026-08-18LYONS GARY A900
2026-08-18LYONS GARY A5,000
2026-08-17LYONS GARY A5,000
2026-08-17LYONS GARY A1,900
2026-08-17LYONS GARY A2,600
2026-08-17LYONS GARY A500
2026-08-17LYONS GARY A5,000
2026-06-22Inrig JulaCHIEF MEDICAL OFFICER468
2026-06-12Baynes Roy D.4,500

8-K events

FiledItems
2026-08-04Results of operations · Financial statements and exhibits
2026-07-09Officer or director change
2026-06-16Officer or director change
2026-06-02Entry into a material agreement · Financial statements and exhibits
2026-05-21Officer or director change · Submission of matters to a vote · Financial statements and exhibits
2026-05-11Entry into a material agreement · Creation of a direct financial obligation · Unregistered sales of equity securities · Other events · Financial statements and exhibits
2026-05-04Results of operations · Financial statements and exhibits
2026-04-14Other events
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…

Pharmaceutical Preparations — 같은 업종, 그리고 규모가 비슷한 기업Pharmaceutical Preparations — and other companies of a similar size

SEC가 같은 업종(Pharmaceutical Preparations)으로 분류한 기업이 먼저 오고, 그다음은 제출된 매출로 가까운 순입니다 — 가장 최근 연간 값이며, 연간 값이 없으면 최근 네 분기 합입니다. Companies the SEC assigns to the same industry (Pharmaceutical Preparations) come first, then the nearest by revenue as filed — the latest annual figure, or the last four quarters where no annual one is filed. 순서일 뿐 값이 싸거나 비싸다는 뜻이 아닙니다.Order only — it does not say a company is cheap or expensive.